60,880 Shares in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new stake in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 60,880 shares of the company’s stock, valued at approximately $4,633,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. UBS Group AG raised its stake in shares of Invesco Pharmaceuticals ETF by 132.2% during the third quarter. UBS Group AG now owns 92,123 shares of the company’s stock worth $6,667,000 after purchasing an additional 52,455 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Invesco Pharmaceuticals ETF by 206.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 41,273 shares of the company’s stock worth $2,987,000 after purchasing an additional 27,786 shares in the last quarter. Commonwealth Retirement Investments LLC acquired a new position in shares of Invesco Pharmaceuticals ETF during the 4th quarter worth $1,557,000. Finally, Modera Wealth Management LLC purchased a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter valued at about $538,000.

Invesco Pharmaceuticals ETF Stock Up 0.6 %

Shares of NYSEARCA PJP opened at $79.69 on Thursday. Invesco Pharmaceuticals ETF has a 52 week low of $67.75 and a 52 week high of $80.65. The stock has a market capitalization of $274.93 million, a price-to-earnings ratio of 20.25 and a beta of 0.64. The firm has a 50-day moving average price of $78.02 and a 200 day moving average price of $75.39.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.